SignalHF vs PMcardio

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Implicity
VS
by Powerful Medical

AI Verdict

SignalHF and PMcardio are adjacent tools in the cardiology AI space, both aiming to improve cardiac care. SignalHF focuses on predicting heart failure hospitalizations using data from cardiac implantable electronic devices, enabling proactive intervention. PMcardio, on the other hand, specializes in rapid and accurate interpretation of ECGs to detect a wide range of cardiac conditions at the point of care.

Choose SignalHF if…

Choose SignalHF if you are managing patients with cardiac implantable electronic devices (CIEDs) and need to proactively predict heart failure hospitalizations. This tool excels at analyzing data from various CIEDs (pacemakers, ICDs, CRTs) to identify patients at high risk within 30 days, enabling early intervention and personalized care plans.

View SignalHF →

Choose PMcardio if…

Choose PMcardio if you require rapid and accurate interpretation of ECGs for the assessment of over 50 cardiac conditions at the point of care. This AI platform is ideal for a wide range of healthcare professionals, including emergency physicians and general practitioners, who need expert-level ECG analysis to confidently diagnose conditions like STEMI and reduced LVEF.

View PMcardio →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature SignalHF PMcardio
Pricing Contact for pricing Freemium
Deployment SaaS Mobile app (iOS and Android), Web platform, Enterprise integrations with EHR/CVIS and EMS systems
FDA Status 1 AI-estimated Pending AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

PMcardio

PMcardio offers a mobile app and web platform, making it highly accessible for clinicians at the point of care. Its freemium model allows users to experience the tool before committing, and user reviews highlight its ease of use and advanced diagnostic capabilities. SignalHF is a SaaS deployment, and while it offers a unified platform, there is less information available regarding its direct user experience or mobile accessibility.

Clinical Value

PMcardio

PMcardio is CE-certified and clinically validated in over 25 studies, trusted by over 100,000 clinicians, and detects over 50 cardiac conditions with high accuracy, including STEMI and reduced LVEF. SignalHF is FDA-cleared and predicts heart failure hospitalizations within 30 days by analyzing CIED data, and has been validated in the FORESEE-HF study. However, PMcardio's broader range of detectable conditions and extensive clinical validation in numerous studies suggest a wider clinical applicability and proven impact.

Pricing & Value

PMcardio

PMcardio offers a transparent freemium model with a free plan for 5 ECG analyses per month and a clear pricing structure for individual, team, and organizational plans. SignalHF's pricing is not publicly specified, requiring direct contact for details, which can be a barrier to initial assessment of value. PMcardio's accessibility through a free tier provides immediate value and allows potential users to evaluate its utility without upfront cost.

Enterprise Readiness

PMcardio

PMcardio offers enterprise integrations with EHR/CVIS and EMS systems, along with dedicated plans for teams and organizations, indicating a strong focus on large-scale deployment and workflow integration. SignalHF is deployed as SaaS and is compatible with various CIEDs, suggesting enterprise capability, but specific integration details and organizational-level features are less explicitly detailed in the provided information.

Innovation

PMcardio

PMcardio features AI explainability with heatmaps (ECGxplainu2122) and detects over 50 cardiac conditions, including novel approaches to STEMI and OMI detection (Queen of Heartsu2122) and reduced LVEF (LVsenseu2122) from ECGs. SignalHF offers a manufacturer-agnostic AI algorithm for heart failure prediction using CIED data, which is innovative in its compatibility across devices. However, PMcardio's visual AI explainability and broader diagnostic scope demonstrate a more diverse and cutting-edge approach to AI in cardiology.

Support & Docs

Tie

Both tools are designed for healthcare professionals, implying a need for robust support and documentation. PMcardio's app store presence indicates in-app customer support via Zendesk and a help center with FAQs and tutorials. SignalHF, as an enterprise SaaS solution, would also necessitate comprehensive support and documentation, though specific details are not provided in the structured facts or search results. Without explicit comparative information, it's difficult to definitively pick a winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature SignalHF PMcardio
Name SignalHF PMcardio
Company Implicity Powerful Medical
Description FDA-cleared AI algorithm that predicts heart failure hospitalizations within 30 days by analyzing data from various cardiac implantable electronic devices, enabling early intervention and personalized care. CE-certified AI platform that interprets ECGs to assess over 50 cardiac conditions rapidly and accurately. Clinically validated in more than 25 studies and trusted by over 100,000 clinicians, it delivers rapid, expert-level interpretations, empowering various healthcare professionals to act with confidence at the point of care.
Regulatory Clearance FDA-cleared CE-certified
Key Features FDA-cleared AI algorithm for heart failure prediction; Predicts heart failure hospitalizations within 30 days; Manufacturer-agnostic compatibility with various CIEDs (pacemakers, ICDs, CRTs); Analyzes physiological data, demographics, lead measurements, episodes, and therapies; Generates automatic alerts for care teams based on risk scores; Enables early intervention and personalized care plans; Unified platform for centralizing cardiac implantable device data; AI-driven alert management to filter and highlight relevant events Instant AI-powered ECG interpretations; Detection of 50+ ECG findings (including STEMI/OMI, rhythms, reduced LVEF, conduction disorders); Queen of Heartsu2122 - STEMI and OMI Detection; LVsenseu2122 - Reduced LVEF Detection; ECGxplainu2122 - Visual AI Explainability with heatmaps; Core AI - Detects 36 core diagnoses (arrhythmias, conduction blocks, heart blocks, chamber hypertrophies); Automatic analysis of heart rate, axis, P wave, PR, QRS, and QT/QTc intervals; Culprit Artery AI confidence scores with 3D heart visualization

Videos

Demos, reviews, and walkthroughs featuring SignalHF and PMcardio.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

SignalHF centralizes and standardizes cardiac implantable electronic device (CIED) data, offering AI-driven alert management and smart workflow automation for remote monitoring teams. PMcardio offers enterprise integrations with EHR/CVIS and EMS systems, allowing for export of data and reports, and is designed to provide rapid, expert-level ECG interpretations at the point of care for various healthcare professionals.
SignalHF is an FDA-cleared AI algorithm that predicts heart failure hospitalizations within 30 days by analyzing CIED data. PMcardio's AI ECG models have been validated in over 25 clinical studies, demonstrating 2x sensitivity for early STEMI detection, over 60% reduction in false STEMI alarms, and 98.3% accuracy in identifying atrial fibrillation.
SignalHF is specifically designed for cardiology teams managing patients with CIEDs for heart failure surveillance, enabling early intervention based on predictive risk scores. PMcardio is suitable for a broader range of specialties including cardiology, emergency medicine, and internal medicine, providing instant AI-powered ECG interpretations for over 50 cardiac conditions, including STEMI/OMI and reduced LVEF.
While specific learning curve details aren't provided, SignalHF's 'clear factors, clear actions' approach suggests a streamlined process for interpreting alerts and identifying next steps. PMcardio is designed for rapid, automated diagnostic support and is trusted by over 100,000 clinicians, implying a user-friendly interface for quick adoption in high-pressure environments.
PMcardio's enterprise plans include advanced dashboards and insights, and the ability to ingest and export data to EHR, which could support audit trails. SignalHF's AI-driven alert management and smart workflow automation suggest a structured process where actions based on alerts could be tracked, but specific audit-trail features are not detailed.
SignalHF offers a unified platform for centralizing cardiac implantable device data, which would be beneficial for multi-site management. PMcardio is trusted by over 150 hospitals worldwide and offers enterprise integrations, indicating its suitability for large-scale deployments and system-wide cardiac care coordination.

Backers

Who funded each tool's parent company.

SignalHF

PMcardio

AI Tool Finder
AI-powered search. Results may not be comprehensive.